Genentech's ranibizumab injection (Susvimo) has received FDA approval for the treatment of diabetic retinopathy. The ...

The Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) for the treatment of patients with ...

Roche (RHHBY) is planning to move a new antibiotic into late stage clinical trials after early studies showed it had ...

Researchers said a single daytime sample of serum 17-hydroxyprogesterone and/or androstenedione is sufficient to monitor ...

FDA approves RHHBY's Susvimo for diabetic retinopathy, its third indication, offering 9-month relief with one treatment.

Roche (OTCQX:RHHBY) (OTCQX:RHHBF) said that an advisory panel of the European Medicines Agency (EMA), endorsed its Itovebi ...

And Arcutis Biotherapeutics announced approval of roflumilast (Zoryve) topical foam 0.3% for plaque psoriasis of the scalp ...

NVO CEO exits amid pressure. Sanofi is set to buy VIGL. Pfizer inks $1.25B 3SBio deal. FDA okays Roche eye drug for new indication. Merck starts key cancer study.

The FDA approved Susvimo 100 mg/mL to treat diabetic retinopathy, according to a press release from Genentech.The approval was supported by positive 1-year data from the phase 3 Pavilion study in ...

The US Food and Drug Administration (FDA) has approved Roche’s (ROG: SIX) Susvimo (ranibizumab injection) 100mg/mL for the ...

Here's a recap of the week’s most important stories.

Basel: Roche has received approval from the US Food and Drug Administration (FDA) for Susvimo (ranibizumab injection) 100 ...